. 2017 Feb 2;5(1):16–22. doi: 10.14218/JCTH.2016.00052

Table 2. Health outcomes by patient subpopulation (per 10,000 patients).

Cases of:	Treatment naïve non-cirrhotic		Treatment naïve cirrhotic		Treatment experienced non-cirrhotic		Treatment experienced cirrhotic
Cases of:	2^nd Gen DAA	1^st Gen DAA + not treated	2^nd Gen DAA	1^st Gen DAA + not treated	2^nd Gen DAA	1^st Gen DAA + not treated	2^nd Gen DAA	1^st Gen DAA + not treated
Hepatic decompensation	-	1,990.8	1,533.9	3,883.7	326.9	2,211.4	1,444.0	4,143.4
Hepatocellular carcinoma	23.7	1,493.3	1,397.7	2,771.4	264.6	1,656.2	1,345.2	2,923.2
Liver transplantation	-	273.9	229.4	592.5	44.2	304.2	215.8	632.6
Liver-related death	20.5	2,718.6	2,417.4	5,506.9	456.4	3,017.4	2,302.3	5,847.9
Life years	19.5	17.9	17.3	14.6	19.2	17.7	17.4	14.3
Quality adjusted life years	16.2	14.1	13.8	11.0	16.0	13.9	13.9	10.6

1^st Gen DAA, first generation direct-acting antiviral agents; 2^nd Gen DAA, second generation direct-acting antiviral agents. Analysis only includes patients with hepatitis C genotype 1. Results are presented per 10,000 patients.